TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04177524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Background Mode
Description: The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Mode
Description: In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Mode
Description: In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Detect Mode
Description: In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Detect Mode
Description: In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Detect Mode
Description: In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle.
Study: NCT00510029

Intervention type: DRUG
Group type: OTHER
Intervention: GAP-134
Description: atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
Study: NCT02974361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Lysine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen-LDH
Study: NCT02406144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study: NCT03167437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab inhibits the bioactivity of human IL-12 and IL- 23 by preventing these cytokines from binding to the IL- 12Rbeta1 receptor protein expressed on the surface of immune cells. It is FDA approved for the treatment of adult patients with active psoriatic arthritis and more recently, in September 2016, ustekinumab has been approved for the treatment of patients with Crohn s disease.
Study: NCT04173273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Dose A taken by mouth, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Dose B taken by mouth, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet taken by mouth, once daily.
Study: NCT02406144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT01794949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Integrity stent
Description: Drug eluting stents used to treat coronary artery blockages

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Integrity stent
Description: Drug eluting stents used to treat coronary artery blockages
Study: NCT01583725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal responses
Description: Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal responses
Description: Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal responses
Description: Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal responses
Description: Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid meal responses
Description: Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI responses to food-cues
Description: Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI responses to food-cues
Description: Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI responses to food-cues
Description: Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI responses to food-cues
Description: Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fMRI responses to food-cues
Description: Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
Study: NCT03509688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir+resveratrol
Description: entecavir+resveratrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir+thymosin α1
Description: entecavir+thymosin α1
Study: NCT04338256

Intervention type: BEHAVIORAL
Intervention: Wellness and Resilience for College and Beyond (Undergraduate College Course)
Description: The course, Wellness and Resilience for College and Beyond was originally developed by James Mazza, PhD and colleagues at the University of Washington as a 10-week course. The course developers adapted their course materials to fit the needs of a 16-week semester for the purpose of this study. The Wellness Course teaches students evidence-based skills for improving mental health from dialectical behavior therapy, acceptance and commitment therapy, and the field of positive psychology. Classes meet for 2.5 hours weekly with approximately half of class time spent on teaching new content (lecture) and the other half spent with students working in small groups on practice and discussion exercises.
Study: NCT04141839

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safer Bars
Description: Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safer Bars
Description: Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
Study: NCT05087576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive helping integrates two distinct areas of research showing that emotional disclosure over writing and support giving improves psychological well-being among healthy and clinical populations. Participants write 4 brief structured writing sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiving Fact writing
Description: Factual Writing has been used with in other writing-based interventions (e.g., expressive writing). It is also completed in 4 brief structured writing sessions.
Study: NCT03246321

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: repetitive ePIPAC-OX
Description: Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
Study: NCT01155258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Given IV
Study: NCT02934568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: Single agent LEE011 or in combination with other treatments
Study: NCT03992612

Intervention type: OTHER
Group type: OTHER
Intervention: control group: usual medical care
Description: The patients received usual medical care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBPM- Mindfulness-Based Pain Management
Description: 8 group session of maindfulness-based treatment to management pain
Study: NCT03647280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
Study: NCT01923961

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HDF NaCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HDF NaCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HDF NaCl

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Predilution Hemodiafiltration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Predilution Hemodiafiltration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Predilution Hemodiafiltration
Study: NCT02186470

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation
Description: Undergo image-guided intensity-modulated APBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo image-guided intensity-modulated APBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: image-guided radiation therapy
Description: Undergo image-guided intensity-modulated APBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Lumpectomy
Study: NCT03187873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chama cha MamaToto
Description: Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
Study: NCT03717298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocoxin-Viusid®
Description: An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year.
Study: NCT02185027

Intervention type: OTHER
Intervention: complications and compliance with GIHP recommendations
Description: Description of complications, compliance, major bleeding events, treatments, reversal strategies.
Study: NCT02572427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education for intubation skills
Description: Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No added education for intubation skills
Description: Routine training in neonatal resuscitation but no added experience in simulation lab.
Study: NCT05144958

Intervention type: DEVICE
Intervention: Totally thoracoscopic LAAO - ATRICLIP
Description: The device for surgical totally thoracoscopic left atrial appendage occlusion AtriClip® Gillinov-Cosgrove™ (AtriClip, AtriCure, Dayton, OH, USA) consists of an automatically closing clip placed in a deployment loop on a disposable holder with the head articulation of 60 degrees side-to-side and up/down. The several novel features of the system in comparison to previous ones, such as its length, maneuverability and releasing system, enable it to be used in a totally thoracoscopic fashion. The AtriClip® PRO has parallel titanium crossbars that equalize the force over the tissue trabeculations of the LAA during deployment, ensuring a sealed line at the base of the LAA orifice, as confirmed in preclinical and clinical studies. The clip can be opened and closed repeatedly before final deployment when only the correct placement is confirmed in TEE.

Intervention type: DEVICE
Intervention: Percutaneous LAAO - WATCHMAN
Description: Using a modified Seldinger technique a vessel dilator and a guidewire are inserted into the femoral vein. Under trans-esophageal echocardiography and fluoroscopy guidance, an interatrial septum is punctured using typical trans-septal access. The pigtail catheter is placed in the distal portion of the left atrial appendage and then the access sheath is inserted. After choosing the appropriate Watchman size the device is deployed and seals the left atrial appendage.

Intervention type: DEVICE
Intervention: Hybrid- minimally invasive LAAO - LARIAT
Description: LARIAT system consists of: A) endocardial magnet-tipped guidewire. It is placed inside the left atrial appendage through the introduction of a catheter into the femoral vein; B) epicardial magnet-tipped guidewire. It is placed on the outside of the left atrium through the atrial appendage puncture of the pericardium. Each wire has a magnet of opposite polarity enabling end-to-end alignment; C) A compliant occlusion balloon catheter to identify the LAA and allow for a very precise and effective seal of the left atrial appendage; D) The LARIAT suture delivery device. It is introduced by an earlier puncture of the pericardium in the vicinity of the left atrial appendage and guided over magnet wire onto the base of the LAAO. With the LARIAT suture delivery device, the lumen of the left atrial appendage is closed from outside the heart, resulting in the elimination of the thrombus source.
Study: NCT04298944

Intervention type: BEHAVIORAL
Intervention: Emotional/ Behavioural assessments
Description: Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
Study: NCT04357769

Intervention type: OTHER
Intervention: PSS (Perceived Stress Scale)
Description: Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks

Intervention type: OTHER
Intervention: PSS (Perceived Stress Scale)
Description: Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks

Intervention type: OTHER
Intervention: PSS (Perceived Stress Scale)
Description: Self-administered scale for the evaluation of the stress perceived by the subject in the last weeks

Intervention type: OTHER
Intervention: GAD-7 (7-item Generalized Anxiety Disorder)
Description: Self-administered scale for the evaluation of anxiety symptoms in the last weeks

Intervention type: OTHER
Intervention: GAD-7 (7-item Generalized Anxiety Disorder)
Description: Self-administered scale for the evaluation of anxiety symptoms in the last weeks

Intervention type: OTHER
Intervention: GAD-7 (7-item Generalized Anxiety Disorder)
Description: Self-administered scale for the evaluation of anxiety symptoms in the last weeks

Intervention type: OTHER
Intervention: PHQ-9 (9-item Patient Health Questionnaire)
Description: Self-administered scale for the evaluation of depressive symptoms in the last weeks

Intervention type: OTHER
Intervention: PHQ-9 (9-item Patient Health Questionnaire)
Description: Self-administered scale for the evaluation of depressive symptoms in the last weeks

Intervention type: OTHER
Intervention: PHQ-9 (9-item Patient Health Questionnaire)
Description: Self-administered scale for the evaluation of depressive symptoms in the last weeks
Study: NCT04232696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuspera Implantable Sacral Nerve Stimulation System
Description: Stimulation of the Sacral Nerve.
Study: NCT04074356

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical measure questionnaires
Description: Collection of patient reported symptoms and perception of health
Study: NCT04357769

Intervention type: OTHER
Intervention: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Description: Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks

Intervention type: OTHER
Intervention: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Description: Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks

Intervention type: OTHER
Intervention: SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales
Description: Self-administered scale for the evaluation of sub-threshold psychotic symptoms in the last weeks

Intervention type: OTHER
Intervention: Zaritt Burden Interview
Description: Self-administered scale for the evaluation of severe mental disorder patients' caregiver burden
Study: NCT03176069

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation and Comparison of women pelvic floor with and without sexual dysfunction
Description: Pelvic floor muscles will also be evaluated by electromyographic biofeedback.